04:39 PM EDT, 10/03/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) said late Thursday it has completed enrollment in its late-stage HARMONi clinical trial from sites in North America, Europe, and China, with topline data expected in mid-2025.

The study is evaluating ivonescimab plus platinum-doublet chemotherapy against placebo plus platinum-doublet chemotherapy with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor, the oncology company said.

Price: 18.80, Change: +0.19, Percent Change: +1.01